Medical Properties Trust, Inc. is a self-advised real estate investment trust (REIT) formed in 2003 and headquartered in Birmingham, Alabama. The company acquires and develops net-leased hospital facilities and leases them to healthcare operators under long-term agreements, while also providing mortgage loans secured by hospital real estate. As of September 30, 2026, MPT owned approximately 365 facilities with roughly 37,000 licensed beds across nine countries on three continents, making it one of the world's largest owners of hospital real estate.
Investors follow MPT primarily for its income-oriented business model, which generates rental revenue through long-term, typically net leases where tenants bear most property operating costs. The company's competitive positioning rests on its scale in hospital real estate and its financing model, which helps operators unlock the value of their real estate to fund facility improvements and technology upgrades. However, tenant concentration and credit risk have become defining themes after two major tenants filed for bankruptcy in recent years. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, MPT shares moved from a closing price of approximately $2.63 to $1.75, a decline of about 33%. The move was not a single-day event but a steady deterioration punctuated by sharp sell-offs following third-quarter results and subsequent analyst actions.
The quarterly picture is even more pronounced. Roughly three months earlier, MPT closed near $4.08, meaning the stock has shed approximately 57% over the trailing quarter. This extended drawdown reflects a sustained repricing driven by tenant credit concerns, rising borrowing costs, and persistent questions about the company's dividend and balance sheet rather than any isolated catalyst.
The most significant near-term catalyst was MPT's third-quarter 2026 earnings report, released in late October. The company posted revenue of roughly $250.1 million and NFFO of $0.11 per share, down from $0.13 per share in the year-earlier period. Management cited the non-payment of September rent by Healthcare Systems of America (HSA), a key cash-basis tenant, as a drag on results, reducing quarterly NFFO by about two cents per share.
The earnings miss triggered a wave of analyst actions. RBC Capital downgraded MPT to Underperform from Sector Perform and cut its price target from $4.50 to $2.00, citing tenant challenges and liquidity concerns. BNP Paribas subsequently lowered its rating to Neutral, and Bank of America reiterated a Sell rating with a $1.75 price target. These downgrades reinforced negative sentiment and contributed to heavy selling volume.
Elevated short interest added further pressure. Reports in early November indicated short interest in MPT had reached roughly 25%, placing the stock among the most heavily shorted names in the micro- and small-cap healthcare REIT segment. This positioning reflected broader market skepticism about dividend sustainability, leverage, and the company's ability to collect full contractual rent from its operators.
The longer-term decline is rooted in a multi-year restructuring effort following the bankruptcies of two major tenants, Steward Health Care in 2024 and Prospect Medical Holdings in 2025. These events removed significant rental income, forced asset sales and dividend cuts, and pushed MPT to re-lease facilities to new operators under rent structures that ramp toward full contractual levels over time.
Over the trailing quarter, investors have focused on whether those replacement tenants can reach stabilized rent. The company completed a roughly $2.4 billion secured-note refinancing at a coupon near 9.25%, extending its debt runway but leaving interest expense elevated. Asset sales generated gains and helped reduce debt, yet the market has continued to discount the stock amid concerns that cash rent recovery, refinancing costs, and dividend coverage may not align as quickly as management targets. This combination of credit risk, leverage, and ongoing tenant uncertainty has kept MPT under sustained pressure. From what I see, the refinancing details stand out as particularly important to track.
Looking ahead, the key variable for MPT is whether its portfolio reaches its targeted cash-rent trajectory. Management has stated that pro forma annualized cash rent is expected to exceed $1 billion, with 2027 portfolio cash rents also projected above that level even after asset sales. The timing of HSA's return to full rent payment is a central watch item, as is the performance of other re-tenanted operators.
Investors should also monitor MPT's debt and refinancing activity, including progress on extending its revolving credit facility and pushing out near-term maturities. Interest-rate conditions and healthcare policy, including potential changes to Medicaid funding, represent additional macro-level risks. Dividend declarations will remain a focal point given the elevated yield and the market's focus on payout sustainability. These factors, rather than any single event, are likely to shape MPT's direction in the months ahead. I’m watching this closely as the rent recovery timeline unfolds.
In my analysis of stocks like this, I often turn to automated strategies for additional perspective. Tickeron’s AI Trading Bots provide a range of data-driven approaches across different timeframes and market conditions, which can help compare how various signals align with fundamental concerns such as tenant credit and leverage. This section features top-performing bots based on recent results, offering a useful reference without replacing core research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 41 cases where MPT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 73%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MPT's RSI Indicator exited the oversold zone, 22 of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 49%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 39 of 57 cases where MPT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for MPT just turned positive on November 19, 2026. Looking at past instances where MPT's MACD turned positive, the stock continued to rise in 30 of 47 cases over the following month. The odds of a continued upward trend are 64%.
Following a +7.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where MPT advanced for three days, in 164 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for MPT entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.240) is normal, around the industry mean (3.134). MPT has a moderately low P/E Ratio (-36.200) as compared to the industry average of (30.791). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.649). MPT's Dividend Yield (0.199) is considerably higher than the industry average of (0.050). P/S Ratio (1.994) is also within normal values, averaging (6.013).
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. MPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PublishingBooksMagazines